Cline Scientific 2020: Pioneering Cancer and Stem Cell Research
We hope your New Year is off to a good start! A lot has happened at Cline Scientific since we last reached out, and we are excited to share with you what's in store for 2020.
As we dive deeper into the world of cancer diagnostics, stem cell research, and regenerative medicine, Cline is officially transitioning from a technology innovator into a full-blown biotech company.
As part of this transition, we are excited to also present a new look to Cline’s website and share our latest projects and goals, so please visit the new site now on clinescientific.com or click the image below (pdf only).
We’re Not Just A Technology Innovator Anymore
At the end of 2019, we announced that we acquired Liv Diagnostics AB, a company whom we collaborated closely with since their founding in 2016. This transaction marks the start of a new era at Cline, where we will not only develop and provide cutting-edge technologies, but also pioneer new medical products as a biotech company.
One such product we have developed is a unique cancer diagnostics tool. It measures the migration behavior of cancer cells, which will provide an indicator of the cancer’s aggressiveness and a prediction of metastasis.
A New Era - Increasing Cancer Survival Rates
This information is critical because metastasis causes 90% of all deaths in cancer. Our product provides direct and quantified information on the risk of metastasis by analyzing the migration behavior of living cells. Our goal is to increase the chances of survival and make personalized medicine possible in this field!
The product has currently achieved promising results in measuring the migration capacity of different types of breast cancer cell lines. We are now actively working to repeat and verify those results in order to take the project to the next step towards clinical trials. Please follow us on our journey as we innovate the cancer diagnostics field!
Strengthening Our Research and Collaboration Efforts
We are continuing to strengthen our oncology and stem cell R&D efforts through joint collaborations with leading pharmaceutical companies and researchers around the world. We would like to welcome Dr Theresa Vincent (Uppsala University), Dr. Petra Szeszula (RISE & Uppsala University) and Dr. Michael Andäng (Uppsala University) to the board of scientific advisors! Their background as founders of Liv Diagnostics and with their knowledge in cancer research and metastasis will be key going forward in the breast cancer diagnostics project.
We look forward to keeping you updated on our latest work! Keep an eye on our webpage and other channels to follow our progress! You are welcome to contact us if you have questions or suggestions, and don’t forget to subscribe on our newsletters.
Best Wishes,
Cline Scientific
Cline Scientific AB
Argongatan 2C
431 53 Mölndal
Telefon: 031-387 55 55
E-post: info@clinescientific.com
Hemsida: www.clinescientific.com
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancerdiagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase.
Cline operates out of Gothenburg, Sweden and was founded in 2012 from a long term research project in surface nanotechnology
